BioSpace News Archive

Darling Ingredients’ (NYSE: DAR) Rousselot® brand and the global leader of collagen-based solutions1, announces the reopening of its upgraded Brazilian innovation lab.

New Orders, Production & Employment Growing; Supplier Deliveries Slowing at Slower Rate; Backlog Growing; Raw Materials Inventories Contracting; Customers’ Inventories Too Low; Prices Increasing; Exports and Imports Growing

Himalaya Therapeutics (“Himalaya”), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics (“CAB”) technology platform, today announced the appointment of Howe Li, M.D., as chief medical officer.

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced the appointment of Vanessa L. Jacoby as Chief Financial Officer.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound IM156, an investigational Protein Complex 1 (PC1) inhibitor, being evaluated for idiopathic pulmonary fibrosis (IPF).

300,000 Canadians are living with type 1 diabetes (T1D). There is no known cause or cure, and the number of new cases is increasing by approximately 5% every year in Canada, with an annual health care cost of over $16 billion*.

The board of directors of Eli Lilly and Company (NYSE: LLY) (the “Board”) has declared a dividend for the second quarter of 2021 of $0.85 per share on outstanding common stock.

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on April 30, 2021, the Company granted stock options to seven new employees of the Company.

COVAXIN effectively neutralizes Brazil variant along with UK variant and India double mutant variant Potential effectiveness against multiple variants reduces the possibility of mutant virus escape According to World Health Organization, the double mutant variant of SARS-CoV-2 has spread to at least 17 countries